The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Serum Vitamin B12 Content and Unsaturated Vitamin B12-Binding Capacity in Myeloproliferative Disease: Value in Differential Diagnosis and as Indicators of Disease Activity

Ann Intern Med. 1969;71(4):719-729. doi:10.7326/0003-4819-71-4-719
Text Size: A A A

The serum unsaturated vitamin B12-binding capacity (UBBC) was found to be of value in distinguishing polycythemia vera from other conditions that are accompanied by an elevated hematocrit or an absolute erythrocytosis and as an indicator of disease activity in polycythemia vera. The serum vitamin B12 level was of lesser value. Increased levels of serum vitamin B12 were observed in 36% and increased levels of UBBC in 70% of patients with untreated polycythemia vera and related myeloproliferative disorders, as contrasted with normal serum vitamin B12 levels in 98% and normal UBBC in 87% of cases of spurious (relative) polycythemia and isolated erythrocytosis (secondary and unclassified polycythemia). Serum vitamin B12 and UBBC levels in polycythemia vera treated only with phlebotomy did not differ from values in untreated cases, whereas patients whose erythroid activity had been controlled by myelosuppressive therapy had levels comparable to those in normal subjects. UBBC values were positively correlated with erythroid activity and leukocyte count. Serial observations indicated that changes in UBBC accompanied and in some cases preceded the occurrence of response and relapse in patients receiving myelosuppressive therapy. Changes in serum B12 levels did not parallel the erythroid response to therapy, nor were B12 levels correlated with the blood count, spleen size, or uric acid values. Chromatographic separation of unsaturated B12 binders showed an increase in both alpha and beta components. The frequent observation of elevated B12 binders without a concomitant rise in serum B12 content in patients with polycythemia vera suggests that some of the B12-binding protein of alpha mobility that is elaborated is abnormal in that it does not bind endogenous vitmain B12.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.